Liu Q, Tan C, Yi L, Wan X, et al. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer. PLoS One 2021;16:e0258605.
PMID: 34780478